| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(6.28) per share which missed the analyst consensus estimate of $(5.0...
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate diseas...
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate f...
-SEC Filing
On September 28, 2025, Jaguar Health, Inc. (the "Company") entered into a securities purchase agreement (the "Purch...
Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, toda...
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant ...